National Nonprofit SoldierStrong Announces Donation of 10 iBots to Veterans During VHA Innovation Experience Conference
STAMFORD, Conn., Oct. 28, 2020 (GLOBE NEWSWIRE) — SoldierStrong, a national nonprofit dedicated to helping military veterans take their next steps forward through the use of revolutionary medical technology, is teaming up with renowned inventor Dean Kamen and DEKA Research and Development Corp. to donate 10 iBOT wheelchairs to individual wounded veterans, co-founder and chairman Chris Meek said Tuesday.
“The goal of this donation is to create lasting, life-changing impacts on the physical and mental health of those who have served our country,” said Meek, who made the announcement remotely during the Veterans Health Administration’s Innovation Experience (iEX) conference in Washington, D.C.
The iBOT wheelchair, which is the brainchild of Kamen in partnership with his company, DEKA, and Johnson & Johnson’s Independent Technology division, is a one-of-a-kind powered wheelchair that climbs stairs, allows users to rise from sitting level to six feet tall, maintains superior balance compared to other products on the market and can withstand travel through sand and standing water.
“Dean Kamen is one of the most recognized and sought-after innovators of our time. He’s made it his life’s work to invent technology, like the iBOT, that improves the lives of others,” Meek said. “With such an iconic status in the science and technology communities, it was a tremendous honor to introduce Dean today at the VHA Innovation Experience. It is also with sincerest gratitude that I thank him for his support of SoldierStrong and his commitment to share DEKA’s life-changing iBOT with veterans who desperately deserve access to this type of disruptive technology.”
The VHA Innovation Experience (iEX) is an annual conference that brings innovators and inventors, medical health experts, veterans, and the public together to showcase and celebrate emerging innovations, partnerships and technologies that improve and save veterans’ lives.
Donations of the iBOTs are the latest effort by SoldierStrong to provide revolutionary medical technologies to help injured veterans lead full lives. SoldierStrong has donated $3.8 million in state-of-the-art medical devices to individual veterans and Veterans Affairs medical centers across the country. These devices include hyper-advanced prosthetics, specialized rehabilitation, and the organization’s signature device, the SoldierSuit exoskeleton used in the rehabilitation of spinal injuries and strokes and to help paralyzed individuals become more mobile. To date, SoldierStrong has donated 22 SoldierSuits, or exoskeletons, that allow some paralyzed veterans to stand and walk again.
A four-year mental health study by the VA Eastern Colorado Health Care System that included use of a SoldierSuit found that paralyzed veterans able to maintain an eye-level view of the world experienced better mental and physical health and a decline in suicidal thoughts or attempts.
“This donation of iBOTs allows SoldierStrong to provide technologies that simultaneously address the needs of physical and mental health,” Meek said. “The iBOT’s unique capabilities will allow veterans who receive a donation to feel secure, independent and enjoy a sense of confidence unmatched by other devices.”
CONTACT: CHRISTINA STROBACK
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer and President and Founder, Powering Precision Health (PPH), Kevin Hrusovsky, will speak today at the Precision Medicine Leaders Summit’s (PMLS) Precision Oncology Conference. Hrusovsky’s keynote presentation, “Revolutionizing Cancer Treatment and Detection with Biomarkers,” will take place at 3:15 p.m., EDT. To register for today’s event visit, https://www.engagez.net/pmls-precisiononcology.
During his presentation, Hrusovsky will discuss advances in highly sensitive multiplex assays, which are enabling researchers to identify and quantify multiple oncology biomarkers simultaneously. This insight paired with the unprecedented ability to see biomarkers in minute concentrations in the blood, as enabled by ultra-sensitive biomarker platforms, is creating new pathways for detecting cancer at its earliest stages. Hrusovsky’s keynote will also speak to the important role of biomarkers in improving the efficacy and safety of immuno-oncology-based treatments by empowering researchers to optimize dosing and minimize toxicity associated with severe side effects.
For more information on Quanterix, please visit www.quanterix.com.
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005851/en/
Staci Didner, 407 734 7325
Change Healthcare Inc. (Nasdaq: CHNG), a leading independent healthcare technology company, today announced its participation in a virtual fireside chat via webcast at the Credit Suisse 29th Annual Healthcare Conference on Wednesday, Nov. 11, 2020 at 11:00 a.m. Eastern Time.
The live webcast and more information about this event may be accessed by visiting the Events and Presentations tab at http://ir.changehealthcare.com. The webcast replay will be available approximately 48 hours after the live webcast ends and will be accessible for 90 days following the conference.
About Change Healthcare
Change Healthcare (Nasdaq: CHNG) is a leading independent healthcare technology company, focused on insights, innovation, and accelerating the transformation of the U.S. healthcare system through the power of the Change Healthcare Platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.
Learn more at changehealthcare.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005185/en/
Evan Smith, CFA
Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference
WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it presented data from two scientific abstracts at the North American Cystic Fibrosis Virtual Conference (NACFC). The two abstracts were also showcased in the NACFC virtual poster gallery and electronically published as a supplement to Pediatric Pulmonology. The live sessions and discussions will take place through October 23rd, 2020. These virtual posters are available to registered attendees on the NACFC online conference platform.
“We were pleased to have the opportunity to present additional preclinical study results in cystic fibrosis at the 2020 NACFC virtual conference that demonstrate ELX-02’s selectivity for read-through of premature stop codons versus native stop codons and its ability to restore production of functional CFTR in patient-derived organoids,” said Dr. Gregory Williams, Chief Executive Officer of Eloxx Pharmaceuticals. “We believe that these results de-risk the current Phase 2 proof of concept clinical trials for ELX-02 in cystic fibrosis. We are continuing to advance our trials in Europe, Israel and the U.S., and we look forward to reporting top line data from the Phase 2 clinical trial program as quickly as possible.”
The details for the two ELX-02 poster presentations are:
Poster Session Presentation Title: “ELX-02 Generates Protein Via Premature Stop Codon Read-through Without Inducing Native Stop Codon Read-through Proteins”
Poster #: 433
Presenter: Dr. Dan Crawford, Eloxx Pharmaceuticals
ELX-02 produces significant read-through of premature stop codons leading to full length proteins, demonstrated using DMS-114 cells with the R213X nonsense mutation in the TP53 gene.
Using three complementary techniques, no evidence of native stop codon read-through products could be detected. These data suggest that ELX-02 does not promote native stop codon read-through at concentrations relevant to premature stop codon read-though.
The results of studies are consistent with the acceptable tolerability profile of ELX-02 across preclinical and clinical studies to date.
Poster Session Presentation Title: “CFTR Restoration By ELX-02 Across CF Nonsense Genotypes: Utilizing Patient-Derived Organoids to Survey Responsive Alleles”
Poster #: 383
Presenter: Dr. Matthew Goddeeris, Eloxx Pharmaceuticals
The patient-derived organoid CFTR FIS assay has enabled the screening of a wide selection of cystic fibrosis nonsense alleles representing >75% of the cystic fibrosis nonsense population. Using this method, we continue to identify new responsive genotypes.
The response of W1282X patient-derived organoids to ELX-02 mediated through read-through positively correlates with CFTR mRNA expression.
Increasing the available CFTR mRNA pool through inhibition of nonsense mediated decay has a synergistic effect on ELX-02 mediated functional CFTR read-through.
These results help guide the interpretation of the patient-derived organoid CFTR FIS assay data by highlighting the importance of considering CFTR expression differences across patient-derived organoids for the applicability of ELX-02 as a potential therapeutic option for cystic fibrosis patients with nonsense alleles.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is
Three generations of one Nevada family – grandmother Patricia Villaseca, her daughter Cyndi Camacho and newborn Elli Camacho, 5 months – all recovered from COVID-19.
Reno Gazette Journal
Governor says state faces “alarming trend” in new cases
Nevadans have to push past “COVID fatigue,” and keep wearing their masks, in order to keep the state’s economy running, Gov. Steve Sisolak told reporters in Las Vegas on Tuesday.
Sisolak, who earlier this month loosened a statewide cap on large gatherings, said officials expected to see some increase in cases after allowing get-togethers of up to 250 people.
But he warned the Silver State now faces an “alarming trend” in new cases and hospitalizations that he fears could put hospitals under strain during flu season.
More: Sisolak raises cap on large gatherings, loosens restrictions on live entertainment venues
Related: Coronavirus updates: Washoe reports 178 new cases, 2nd highest daily number to date
The first-term Democrat said in many cases, people are simply sick of being cooped up at home.
“COVID wasn’t supposed to last this long,” Sisolak added. “We all feel COVID fatigue, and it results in riskier behavior and complacency. We can’t let that happen.
“Unfortunately, this virus doesn’t get fatigued. It’s alive and well. We can’t get tired, because the virus isn’t tired.”
Governor Steve Sisolak during a press conference on Monday, Aug. 3, 2020 in the former Assembly chambers inside the Capital in Carson City. (Photo: PROVIDED/Pool Photo by David Calvert/Nevada Independent)
The governor later said he “hoped to never get” to a point where he might have to reimplement strict COVID-prevention measures imposed earlier in the pandemic. He also confirmed the state had submitted its plan for distributing a coronavirus vaccine to federal officials last week.
Nevada’s rate of coronavirus infections has steadily risen in the month since the state eased restrictions on the size of public gatherings, though health officials have cautioned against blaming the increase on bigger get-togethers.
“We are seeing a number of factors that could be contributing to this. I wouldn’t necessarily tie it directly” to the easing of restrictions, Nevada COVID-19 Task Force Director Caleb Cage said Monday. “We are seeing the same climb happen around the country and in fact around the world as well.”
The state’s 14-day rolling average for the positivity rate — which measures community transmission of the virus — began this week at 9.1% for the third consecutive day.
It hadn’t been as high as 9% since Sept. 4 when the state was in the midst of a two-month downward trend that saw the positivity rate drop from 14.3% on Aug. 1 to less than half that by mid-September — hovering below 7% most of the last two weeks of of September before inching up to 7.1% on Sept. 30.
The uptick has been especially pronounced in Washoe County, which now sits at the top of the list when it comes to the rate for new COVID-19 cases.
Washoe ended last week with 561 cases per 100,000
Biopharma stocks, which started the week on a firm footing, lost momentum mid-way through amid market-wide sell-off triggered by waning stimulus hopes.
The week was a quiet one from the perspective of news flow. Johnson & Johnson (NYSE: JNJ) was in the news for both right and wrong reasons. The company’s Phase 3 trial of its coronavirus vaccine was paused due to a trial participant contracting an unexplained illness. On a positive note, the company reported solid quarterly results and lifted its guidance.
Pfizer Inc. (NYSE: PFE), meanwhile, stayed above political pressure and provided a realistic timeframe for filing for emergency use authorization for its vaccine candidate.
Avenue Therapeutics Inc (NASDAQ: ATXI) shares fell from $11 to just under $4 after FDA rejected its opioid pain drug on safety concerns.
Clinical trial disappointments led to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Cyclerion Therapeutics Inc (NASDAQ: CYCN) shelving alpha-1 antitrypsin deficiency and sickle cell disease studies, respectively.
The week witnessed Nasdaq debuts by six biopharma companies, which collectively raised about $650 million in gross proceeds.
Here are the key catalysts for the unfolding week.
American College of Chest Physicians’ CHEST Annual Meeting 2020, being held virtually: Oct. 18-21
The Prostate Cancer Foundation’s 27th Annual Scientific Retreat: Oct. 20-23
IDWeek 2020: Oct. 20-25
American Society of Nephrology, or ASN, Kidney Week 2020 Annual Meeting: Oct. 22-25 (early programs scheduled for Oct. 19-21)
32nd European Organisation for Research and Treatment of Cancer-the National Cancer Institute- the American Association for Cancer Research, or EORTC-NCI-AACR, Symposium: Oct. 24-25
Zosano Pharma Corp’s (NASDAQ: ZSAN) NDA for its migraine drug Qtrypta has a PDUFA action date of Oct. 20. With the company disclosing in late September that it has received a discipline review letter, which raised two concerns about the clinical pharmacology section of the NDA, a decision by the d-day seems unlikely.
The FDA is set to rule on Spectrum Pharmaceuticals, Inc.’s (NASDAQ: SPPI) BLA for SPI-2012 to treat chemotherapy-induced neutropenia. The PDUFA date is Oct. 24.
Pfizer Inc. (NYSE: PFE) is scheduled to present at the ID Week 2020 full results of the pediatric Phase 2 proof-of-concept study of 20vPNC and detailed results from a Phase 2 proof-of-concept study of its potential first-in-class pentavalent meningococcal vaccine candidate.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) will present at the ASN meeting results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran in treating primary hyperoxaluria type 1.
Omeros Corporation (NASDAQ: OMER) is due to present final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. The presentation, in the form of a webcast, is scheduled for Oct. 22.
Mustang Bio Inc (NASDAQ: MBIO), founded by Fortress Biotech (NASDAQ: FBIO), is scheduled to present at the Prostate Cancer Foundation’s annual scientific retreat initial Phase 1 data on CAR-T cell therapy MB-105 in patients with PSCA-positive metastatic castration-resistant prostate cancer. The presentation is fixed for Oct. 23.
View more earnings on IBB
Related Link: 9